As high GATA2 expression and transcriptional activity are linked to poor prognosis in PC (Chiang et al. 2014, He et al. 2014), and GATA2 being considered a transcriptional partner and coactivator for AR, GATA2 is poised as a promising therapeutic target for the inhibition of advanced CRPC. This evidence concerns the gene AR and pachyonychia congenita.